Literature DB >> 15618293

Biological activities of reverse signal transduction through CD137 ligand.

Herbert Schwarz1.   

Abstract

CD137 is a member of the tumor necrosis factor receptor family and a potent regulator of T cell activities. Agonists of CD137 have been used widely and successfully to treat cancer in animal models, and recently, it has become evident that CD137 agonists can also be used to treat autoimmune disease. An aspect of the CD137 receptor/ligand system, which has been comparatively little-explored, is its ability of reverse signaling. Just as is CD137, the CD137 ligand is also expressed as a cell membrane protein, and it too can transduce signals into the cells on which it is expressed. This bidirectional signaling capacity allows the CD137 receptor/ligand system to mediate extensive cross-talk between immune cells and between immune and nonimmune cells. This review summarizes the known activities of the CD137 ligand on the different leukocyte subsets and on cancer cells and discusses their influence on the course of immune responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15618293     DOI: 10.1189/jlb.0904558

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  27 in total

1.  Cross-linking of CD137 ligand modulates immune responses of thioglycollate-elicited mouse peritoneal macrophages.

Authors:  Jun-Sang Bae; Hyeong-Sup Kim; Jae Hong Park; Sang-Hyuk Park; Hyeon-Woo Lee
Journal:  Inflamm Res       Date:  2010-12-24       Impact factor: 4.575

2.  Tumor necrosis factor receptor subfamily 9 (Tnfrsf9) gene is expressed in distinct cell populations in mouse uterus and conceptus during implantation period of pregnancy.

Authors:  Kirsten Eckstrum; Brent M Bany
Journal:  Cell Tissue Res       Date:  2011-05-12       Impact factor: 5.249

3.  Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.

Authors:  Yuan Zhao; Michael Croft
Journal:  Immunol Lett       Date:  2011-10-20       Impact factor: 3.685

4.  A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.

Authors:  Rich-Henry Schabowsky; Kutlu G Elpek; Shravan Madireddi; Rajesh K Sharma; Esma S Yolcu; Laura Bandura-Morgan; Robert Miller; Kathryn J MacLeod; Robert S Mittler; Haval Shirwan
Journal:  Vaccine       Date:  2009-10-29       Impact factor: 3.641

Review 5.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

6.  The change of immunoactivity of dendritic cells induced by mouse 4-1BBL recombinant adenovirus.

Authors:  Kuang Youlin; Weng Xiaodong; Liu Xiuheng; Chen Zhiyuan; Zhu Hengcheng; Chen Hui; Jiang Botao
Journal:  Yonsei Med J       Date:  2010-07       Impact factor: 2.759

7.  Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.

Authors:  Charles Gullo; Liang Kai Koh; Wan Lu Pang; Kian Tong Ho; Shi Hao Tan; Herbert Schwarz
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

8.  Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8(+) T cells.

Authors:  Ian R Humphreys; Seung-Woo Lee; Morgan Jones; Andrea Loewendorf; Emma Gostick; David A Price; Chris A Benedict; Carl F Ware; Michael Croft
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

9.  Novel transmembrane protein 126A (TMEM126A) couples with CD137L reverse signals in myeloid cells.

Authors:  Jun-Sang Bae; Joong-Kook Choi; Ji-Hoi Moon; Eun-Cheol Kim; Michael Croft; Hyeon-Woo Lee
Journal:  Cell Signal       Date:  2012-08-01       Impact factor: 4.315

10.  CD137-CD137 Ligand Interactions in Inflammation.

Authors:  Byungsuk Kwon
Journal:  Immune Netw       Date:  2009-06-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.